By Denny Jacob
Shares of GeneDx Holdings shot up 24% following higher-than-expected revenue in its fourth quarter.
Shares were trading around $95. Over the last year, the stock is up nearly 1800%.
The patient health intelligence company recorded revenue of $95.3 million, up 64% from $58.1 million in the prior-year period. Analysts polled by FactSet had expected $82.2 million.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 18, 2025 10:14 ET (15:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。